FDA extends review period for Ascendis Pharma's first drug

Ascendis Pharma has to wait three more months for the FDA to give its verdict on the firm's drug lonapegsomatropin for treating pediatric growth hormone deficiency.

Photo: Kevin Grønnemann

Just two weeks before the deadline, the US Food and Drug Administration (FDA) has extended the review period for Ascendis Pharma's first drug candidate lonapegsomatropin, according to an Ascendis Pharma press release.

Now, the FDA must make a decision on lonapegsomatropin, also known as Transcon hgh, by Sept. 25, which is a three-month extension in total.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs